Georgia Clinical Trials Report — June 2026

For Georgians considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their conclusion. Across the state, 130 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 13 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various mental health conditions, cancers, and cardiovascular issues are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder
• Advanced breast cancer
• Sickle cell disease
• Heart failure
• Cervical cancer
• Fallopian tube cancer
• COPD
• Aortic valve insufficiency
• Breast cancer
• Bladder pain syndrome

Groundbreaking Research Launches Across Georgia

This month, Georgia welcomes 41 new clinical trials, a notable increase from the 38 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine, as well as crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy, safety, and tolerability of aleniglipron.
• Pfizer is leading an important Phase 3 vaccine trial: NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This study aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants.
• For individuals experiencing migraines, Kallyope Inc. is sponsoring two significant Phase 3 trials. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," targets 1,800 participants. Additionally, NCT07674654 is a "Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," seeking 1,000 participants to evaluate the safety and tolerability of intermittent use.
• For adults with obesity or overweight and Type 2 Diabetes Mellitus, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is also sponsoring NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This Phase 3 study plans for 1,100 participants to assess the long-term efficacy, safety, and tolerability of aleniglipron.
• Emory University is leading NCT07651631, the "Rapid Evacuation and Access of Cerebral Hemorrhage Registry," an observational study aiming for 2,500 participants to quantify the real-world effect of minimally invasive surgery in patients with acute spontaneous supratentorial intracerebral hemorrhage.
• A novel prenatal study, NCT07643896, "The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study," sponsored by BillionToOne Inc., plans to enroll 1,000 participants to demonstrate a circulating fetal cell (CFC) based approach to non-invasive fetal risk assessment.

New Research Opportunities Across Conditions and Interventions

The 41 new trials opening this month in Georgia cover a diverse range of health conditions, with a strong focus on metabolic health and neurological conditions. The most common conditions addressed by these new studies include:

• Obesity (4 trials)
• Overweight (4 trials)
• Autism spectrum disorder (2 trials)
• Chronic weight management (2 trials)
• Type 2 diabetes mellitus (2 trials)
• Chronic pain (2 trials)
• Migraine (2 trials)
• Autism (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 27 of the new studies. Behavioral interventions are also well-represented with 5 new trials, alongside other types of research including devices, biological treatments, and dietary supplements.

Geographic Reach: Atlanta Leads, Opportunities Across Georgia

Georgia's clinical research landscape continues to be robust, with 1,976 clinical trials currently recruiting across 100 cities and 1,279 research sites statewide. This month, the majority of new research initiatives are concentrated in the Atlanta metropolitan area, which saw 25 new trials open. However, opportunities are also expanding in other parts of the state:

• Woodstock (5 new trials)
• Decatur (5 new trials)
• Marietta (3 new trials)
• Roswell (2 new trials)
• Columbus (2 new trials)
• Norcross (2 new trials)
• Stockbridge (2 new trials)
• Union City (2 new trials)
• Lawrenceville (2 new trials)

This distribution ensures that residents in various regions of Georgia have access to cutting-edge research, even as Atlanta remains a central hub for clinical investigations.

Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 41 new trials launched this month, 5 are actively seeking healthy volunteers. Statewide, a total of 175 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Georgia are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 6 include children as participants, and 36 include older adults, ensuring that research benefits diverse age groups. Additionally, 3 new trials are female-only, and 1 is male-only, addressing specific health needs. Academic institutions continue to play a vital role in the state's research ecosystem, with Emory University sponsoring 5 of the new trials and Morehouse School of Medicine sponsoring 2. Industry sponsors are also driving significant research efforts, with 27 new trials sponsored by pharmaceutical companies such as AstraZeneca, Eli Lilly and Company, Gasherbrum Bio, Inc., and Kallyope Inc.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Georgia.